Skip to content
TimeLinq

Asset comparator

Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.

  • Ambu
  • Novo Nordisk

Comparative performance (base 100)

Each asset is worth 100 at October 20, 2025; a value of 120 means +20% since that date (latest common date: October 16, 2026).

Indicators

"Not applicable" indicates a metric that has no meaning for this type of asset: it should not be compared.

IndicatorAmbuStockNovo NordiskStock
Performance and risk
Performance over the periodChange in price between the first and last common dates.−25.6%−27.8%
Annualized performanceAverage annual return that would produce the same total performance.−25.9%−28.1%
Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates.37.9%46.4%
Maximum DrawdownLargest decline from peak to subsequent trough over the period.−45.3%−43.1%
Sharpe RatioReturn achieved above the risk-free rate (5.10%), per unit of volatility. The higher it is, the better risk was rewarded over the period.-0.67-0.54
1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR).−2.9%−4.2%
Fundamentals
Market capitalizationTotal market value of all shares (or circulating tokens for a crypto).20.42B DKK1.15T DKK
P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid.40.89.7
Price-to-SalesMarket capitalization divided by annual revenue.3.33.5
Net marginShare of revenue retained as profit.8.2%35.3%
Return on equityReturn on equity (ROE).8.4%59.8%
Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year.+8.8%+2.1%
Dividend yieldAnnual dividend relative to the share price.0.52%4.51%
Debt / equityFinancial debt relative to shareholders' equity.9%63%

Correlations over the period

From −1 to 1: close to 1, the two assets rise and fall together; close to 0, they move independently.

  • Ambu / Novo Nordisk0.25

Information provided for educational purposes only. It does not constitute investment advice or a personalized recommendation. Past performance is no guarantee of future results.